Traders sold shares of Eli Lilly and Co. (NYSE:LLY) on strength during trading hours on Tuesday. $47.14 million flowed into the stock on the tick-up and $62.68 million flowed out of the stock on the tick-down, for a money net flow of $15.54 million out of the stock. Of all equities tracked, Eli Lilly and had the 0th highest net out-flow for the day. Eli Lilly and traded up $0.72 for the day and closed at $79.88

A number of research analysts have weighed in on the company. Citigroup Inc. reiterated a “buy” rating on shares of Eli Lilly and in a report on Wednesday, August 3rd. Argus upped their target price on Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 target price on the stock in a report on Friday, July 29th. BMO Capital Markets reiterated a “buy” rating and set a $94.00 target price on shares of Eli Lilly and in a report on Wednesday, July 27th. Finally, Leerink Swann reiterated an “outperform” rating and set a $105.00 target price on shares of Eli Lilly and in a report on Saturday, August 13th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $96.85.

The firm’s 50-day moving average is $79.51 and its 200-day moving average is $76.76. The stock has a market cap of $84.49 billion, a PE ratio of 34.43 and a beta of 0.20.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/traders-sell-eli-lilly-and-co-lly-on-strength-lly-2.html

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, hitting analysts’ consensus estimates of $0.86. The company earned $5.40 billion during the quarter, compared to the consensus estimate of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. Eli Lilly and’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.90 earnings per share. Equities analysts predict that Eli Lilly and Co. will post $3.59 earnings per share for the current fiscal year.

In other Eli Lilly and news, Director Jackson P. Tai acquired 2,560 shares of Eli Lilly and stock in a transaction that occurred on Friday, August 12th. The stock was bought at an average price of $80.42 per share, with a total value of $205,875.20. Following the completion of the purchase, the director now directly owns 42,110 shares of the company’s stock, valued at approximately $3,386,486.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Donald A. Zakrowski sold 1,213 shares of the business’s stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $83.16, for a total transaction of $100,873.08. Following the completion of the transaction, the insider now directly owns 1,300 shares of the company’s stock, valued at approximately $108,108. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock worth $4,979,889,000 after buying an additional 1,350,329 shares during the period. Franklin Resources Inc. increased its position in shares of Eli Lilly and by 2.5% in the second quarter. Franklin Resources Inc. now owns 28,430,876 shares of the company’s stock worth $2,238,939,000 after buying an additional 685,898 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Eli Lilly and by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 26,674,046 shares of the company’s stock worth $2,100,581,000 after buying an additional 289,681 shares during the period. JPMorgan Chase & Co. increased its position in shares of Eli Lilly and by 3.0% in the second quarter. JPMorgan Chase & Co. now owns 23,184,616 shares of the company’s stock worth $1,825,790,000 after buying an additional 668,184 shares during the period. Finally, BlackRock Fund Advisors increased its position in shares of Eli Lilly and by 2.8% in the second quarter. BlackRock Fund Advisors now owns 17,206,391 shares of the company’s stock worth $1,355,003,000 after buying an additional 475,012 shares during the period. 75.06% of the stock is owned by institutional investors.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.